Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Italy launches massive genetic database to match cancer patients with better treatments

NCT ID NCT05918666

Knowledge-focused Sponsor: Federation of Italian Cooperative Oncology Groups Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This observational study aims to create a national registry of genetic mutations found in advanced solid tumors. By collecting data from over 2,000 Italian patients, researchers hope to improve access to innovative therapies. The study does not test a new treatment but gathers information to guide future precision medicine efforts.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this registry could help match more patients with advanced solid tumors to targeted therapies based on their genetic mutations.
What could go wrong
This is an observational study, not a treatment trial. It collects data but does not test any new drug, so it may not directly improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

2,098 people

The number who actually took part.

Started

Oct 2018

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

patients with solid tumors in advanced stage of disease

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

General Inclusion Criteria for all patients: * Age \>18 years old * Life expectancy 6 months * ECOG performance status 2 * Diagnosis of malignant solid tumor, in advanced stage * Informed consent to data registration and for privacy purposes Additional inclusion criteria for patients that have already carried out a genetic characterisation extended by high throughput methods: ● Availability of the result of the broad spectrum analysis of genetic alterations carried out with high throughput methods on biological samples Additional inclusion criteria for patients that perform the molecular-genetic screening using Foundation Medicine services or in selected italian laboratories: * one of the following criteria: * Patients diagnosed with NSCLC not squamous, not pretreated; * Patients with biliary tract, pancreatic, esophagus, stomach, thymus, CNS, nasopharynx, salivary glands, endometrium and urothelium cancers; * Patients with any disease (including NSCLC) who are progressing disease after treatment with molecular target drugs. For these patients is the availability of a post- treatment biological sample is necessary; * Patients with cancer of unknown primary (CUP); * Young patients (\<40 years) or patients who have exhausted standard lines of therapy, with any advanced/metastatic tumor which, in the opinion of the investigator, may benefit from a genetic-molecular characterization at broad spectrum aimed at a treatment with molecular target therapies. * availability of biological material for testing. * informed consent for testing. Additional exclusion criteria for patients that perform the molecular-genetic screening using Foundation Medicine services or in selected italian laboratories: ● patients who have already received NGS or other high throughput in the same stage of disease.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Solid tumor are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Solid tumours in advanced stages

Contacts and locations

Locations

  • Day Hospital - Oncologia Medica - Università Campus Biomedico di Roma

    Roma, Italy

  • Dipartimento ad attività integrata di Oncologia - Azienda Sanitaria Universitaria Integrata di Udine Friuli Centrale

    Udine, Italy

  • Dipartimento di Oncologia - A.O.U. San Luigi Gonzaga

    Torino, Italy

  • Divisione di Oncologia Medica e dei Tumori Immunocorrelati - Centro di Riferimento Oncologico

    Aviano, Italy

  • Fondazione IRCCS Istituto Nazionale dei Tumori

    Milan, Italy

  • Istituto Nazionale Tumori - IRCCS Fondazione G. Pascale

    Naples, Italy

  • Niguarda Cancer Center - Ospedale Niguarda e Università degli Studi di Milano

    Milan, Italy

  • Oncologia - AOU Policlinico "G. Martino"

    Messina, Italy

  • Oncologia - Ospedale Sacro Cuore Don Calabria

    Negrar, Italy

  • Oncologia Medica - A.O.U. Policlinico Paolo Giaccone

    Palermo, Italy

  • Oncologia Medica - A.O.U. Seconda Università degli studi di Napoli

    Naples, Italy

  • Oncologia Medica e Brest Unt - Presidio di Brindisi Di Summa-Perrino

    Brindisi, Italy

  • Oncologia Toracica - Istituto Europeo di Oncologia

    Milan, Italy

  • S.C. Oncologia - Fondazione Casa Sollievo della Sofferenza

    San Giovanni Rotondo, Italy

  • S.C. Oncologia - Fondazione IRCCS Policlinico S. Matteo

    Pavia, Italy

  • S.C. Oncologia - IRCCS Arcispedale Santa Maria Nuova

    Reggio Emilia, Italy

  • S.C. Oncologia - Ospedale Humanitas Gradenigo

    Torino, Italy

  • S.C. Oncologia Medica - A.O. S.M. della Misericordia

    Perugia, Italy

  • S.C. di Oncologia Medica - A.O.U. Careggi

    Florence, Italy

  • S.O.D. Clinica Oncologica - A.O.U. Ospedali Riuniti Ancona

    Ancona, Italy

  • Sviluppo di nuovi Farmaci per Terapie Innovative - Istituto Europeo di Oncologia

    Milan, Italy

  • U.O. Oncologia Medica - A.O. Papardo

    Messina, Italy

  • U.O. Oncologia Medica - A.O. S.G. Moscati

    Avellino, Italy

  • U.O. Oncologia Medica - Humanitas Gavazzeni

    Bergamo, Italy

  • U.O. Oncologia Medica - Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori S.r.l. IRCCS

    Meldola, Italy

  • U.O. Oncologia Medica - Ospedale Santa Chiara

    Trento, Italy

  • U.O. Oncologia Medica 2 - Istituto Oncologico Veneto

    Padova, Italy

  • U.O. Oncologia Medica 2 - Stabilimenteo S. Chiara - A.O.U. Pisana

    Pisa, Italy

  • U.O.C. Oncologia - A.O. San Camillo -Forlanini

    Roma, Italy

  • U.O.C. Oncologia - A.O. Sant'Andrea

    Roma, Italy

  • U.O.C. Oncologia - A.O.U. OO.RR. San Giovanni di Dio Ruggi d'Aragona

    Salerno, Italy

  • U.O.C. Oncologia - AORN - Ospedali dei Colli

    Naples, Italy

  • U.O.C. Oncologia - ASST Bergamo ovest

    Treviglio, Italy

  • U.O.C. Oncologia - Asl Napoli 1 Centro - Ospedale del Mare

    Naples, Italy

  • U.O.C. Oncologia Medica - A.O.U. Policlinico Vittorio Emanuele

    Catania, Italy

  • U.O.C. Oncologia Medica - Ospedale Garibaldi Nesima

    Catania, Italy

  • U.O.C. Oncologia Medica - Ospedale San Donato

    Arezzo, Italy

  • U.O.C. Oncologia Medica e Sperimentale - Istituto Tumori Giovanni Paolo II IRCCS

    Bari, Italy

  • U.O.C. di Oncologia medica - A.O.U. Integrata Verona

    Verona, Italy

  • U.O.S. Tumori polmonari IRCCS A.O.U. San Martino IST - Istituto Nazionale per la Ricerca sul Cancro

    Genova, Italy

  • U.O.S.D. Pneumologia Oncologica - San Camillo Forlanini

    Roma, Italy

  • UOC Oncologia Medica - ULSS 2 Marca Trevigiana - P.O. Treviso

    Treviso, Italy

  • Unità di Struttura Complessa Oncologia Medica - ASST Papa Giovanni XXIII

    Bergamo, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.